1. Home
  2. LPA vs ALDX Comparison

LPA vs ALDX Comparison

Compare LPA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

HOLD

Current Price

$2.89

Market Cap

89.2M

Sector

N/A

ML Signal

HOLD

Logo Aldeyra Therapeutics Inc.

ALDX

Aldeyra Therapeutics Inc.

HOLD

Current Price

$5.30

Market Cap

293.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPA
ALDX
Founded
2013
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.2M
293.0M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
LPA
ALDX
Price
$2.89
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.50
AVG Volume (30 Days)
30.7K
1.6M
Earning Date
11-12-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$47,536,343.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$36.25
P/E Ratio
$13.48
N/A
Revenue Growth
7.28
N/A
52 Week Low
$2.55
$1.14
52 Week High
$11.47
$7.20

Technical Indicators

Market Signals
Indicator
LPA
ALDX
Relative Strength Index (RSI) 44.58 53.77
Support Level $2.65 $4.98
Resistance Level $3.15 $5.75
Average True Range (ATR) 0.17 0.47
MACD 0.01 0.07
Stochastic Oscillator 52.68 75.07

Price Performance

Historical Comparison
LPA
ALDX

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Share on Social Networks: